skip to main content


Vectorised gene therapy for muscle and nerve disorders 

VectorY develops an innovative gene therapy platform with a focus on the development of treatments for nerve and muscle diseases. The VectorY platform combines the therapeutic potential of antibodies and gene therapy. The lead products focus on ALS, a fatal disease in which motor nerve cells deteriorate.

The Mibiton funding will be used to set-up the pilot facility, which will produce gene therapy products on a pilot scale.

Alexander Vos, CEO

"VectorY is a rapidly growing company. We are delighted with the support of Mibiton in achieving our goals of providing innovative treatments to patients, suffering from Central Nervous System and neuromuscular disorders."